Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: HYP080
MIFTS: 53

Hypogonadism

Categories: Endocrine diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Hypogonadism

About this section

MalaCards integrated aliases for Hypogonadism:

Name: Hypogonadism 12 77 30 56 45 15 74

Classifications:

MalaCards categories:
Anatomical: Endocrine diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:1924
MeSH 45 D007006
NCIt 51 C9227
SNOMED-CT 69 48130008
UMLS 74 C0020619
Sources

Summaries for Hypogonadism

About this section
Disease Ontology : 12 A gonadal disease that is characterized by diminished functional activity of the gonads.

MalaCards based summary : Hypogonadism is related to hypogonadotropic hypogonadism 23 without anosmia and hypogonadotropic hypogonadism 7 with or without anosmia. An important gene associated with Hypogonadism is GNRH1 (Gonadotropin Releasing Hormone 1), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Menotropins and Testosterone have been mentioned in the context of this disorder. Affiliated tissues include bone, pituitary and prostate, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 77 Hypogonadism means diminished functional activity of the gonads—the testes or the ovaries—that may... more...

Sources

Related Diseases for Hypogonadism

About this section

Diseases related to Hypogonadism via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 535)
# Related Disease Score Top Affiliating Genes
1 hypogonadotropic hypogonadism 23 without anosmia 33.6 GNRH1 GNRHR LHB
2 hypogonadotropic hypogonadism 7 with or without anosmia 33.4 DUSP6 FGF17 FGFR1 GNRH1 GNRHR SPRY4
3 hypogonadotropism 32.2 GNRH1 GNRHR KISS1 KISS1R
4 normosmic congenital hypogonadotropic hypogonadism 30.4 ANOS1 CHD7 DUSP6 FGF17 FGFR1 GNRH1
5 hypogonadotropic hypogonadism 30.3 ANOS1 CHD7 DUSP6 FGF17 FGFR1 FSHB
6 kallmann syndrome 30.3 ANOS1 CHD7 DUSP6 FGF17 FGFR1 GNRH1
7 infertility 30.1 FSHB GNRH1 LHB LHCGR
8 charge syndrome 29.9 ANOS1 CHD7 FGFR1 PROK2 PROKR2
9 precocious puberty 29.7 GNRH1 KISS1 KISS1R LHCGR
10 amenorrhea 29.7 FSHB GNRH1 LHB LHCGR
11 cryptorchidism, unilateral or bilateral 29.4 ANOS1 FGFR1 GNRH1 GNRHR PROK2 PROKR2
12 central precocious puberty 29.3 GNRH1 KISS1 KISS1R
13 cardiomyopathy, dilated, with hypergonadotropic hypogonadism 12.4
14 ataxia - hypogonadism - choroidal dystrophy 12.4
15 hypogonadotropic hypogonadism 1 with or without anosmia 12.4
16 hypogonadotropic hypogonadism 10 with or without anosmia 12.4
17 hypogonadotropic hypogonadism 21 with or without anosmia 12.4
18 hypogonadotropic hypogonadism 8 with or without anosmia 12.4
19 hypogonadotropic hypogonadism 11 with or without anosmia 12.4
20 hypogonadotropic hypogonadism 12 with or without anosmia 12.4
21 hypogonadotropic hypogonadism 13 with or without anosmia 12.4
22 hypogonadotropic hypogonadism 15 with or without anosmia 12.4
23 hypogonadotropic hypogonadism 16 with or without anosmia 12.4
24 hypogonadotropic hypogonadism 20 with or without anosmia 12.4
25 hypogonadism, male 12.4
26 hypogonadotropic hypogonadism 4 with or without anosmia 12.3
27 hypogonadotropic hypogonadism 9 with or without anosmia 12.3
28 hypogonadotropic hypogonadism 14 with or without anosmia 12.3
29 hypogonadotropic hypogonadism 17 with or without anosmia 12.3
30 hypogonadotropic hypogonadism 19 with or without anosmia 12.3
31 hypogonadotropic hypogonadism 22 with or without anosmia 12.3
32 hypogonadotropic hypogonadism 3 with or without anosmia 12.3
33 hypogonadotropic hypogonadism 5 with or without anosmia 12.3
34 hypogonadotropic hypogonadism 18 with or without anosmia 12.3
35 hypogonadotropic hypogonadism 6 with or without anosmia 12.3
36 hypogonadotropic hypogonadism 2 with or without anosmia 12.3
37 leukodystrophy, hypomyelinating, 8, with or without oligodontia and/or hypogonadotropic hypogonadism 12.3
38 deafness-hypogonadism syndrome 12.3
39 leukodystrophy, hypomyelinating, 7, with or without oligodontia and/or hypogonadotropic hypogonadism 12.3
40 hypogonadotropic hypogonadism 24 without anosmia 12.2
41 moyamoya disease 4 with short stature, hypergonadotropic hypogonadism, and facial dysmorphism 12.2
42 hydrocephalus obesity hypogonadism 12.1
43 intellectual disability-dysmorphism-hypogonadism-diabetes mellitus syndrome 12.1
44 retinitis pigmentosa-intellectual disability-deafness-hypogonadism syndrome 12.1
45 cerebellar ataxia and hypergonadotropic hypogonadism 12.0
46 microcephaly hypergonadotropic hypogonadism short stature 12.0
47 ichthyosis and male hypogonadism 12.0
48 hypogonadism-cataract syndrome 11.9
49 hypergonadotropic hypogonadism and partial alopecia 11.9
50 muscular dystrophy, congenital, with infantile cataract and hypogonadism 11.9

Graphical network of the top 20 diseases related to Hypogonadism:



Diseases related to Hypogonadism
Sources

Symptoms & Phenotypes for Hypogonadism

About this section

GenomeRNAi Phenotypes related to Hypogonadism according to GeneCards Suite gene sharing:

27 (show all 22)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.74 FGFR1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-116 9.74 KISS1 KISS1R
3 Increased shRNA abundance (Z-score > 2) GR00366-A-125 9.74 FGFR1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-126 9.74 FGFR1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-132 9.74 KISS1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-137 9.74 KISS1R
7 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.74 KISS1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.74 FGFR1 KISS1 KISS1R LHB
9 Increased shRNA abundance (Z-score > 2) GR00366-A-183 9.74 FGFR1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-199 9.74 LHB
11 Increased shRNA abundance (Z-score > 2) GR00366-A-205 9.74 KISS1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-22 9.74 LHB
13 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.74 FGFR1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.74 FGFR1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.74 LHB
16 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.74 FGFR1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-56 9.74 KISS1R
18 Increased shRNA abundance (Z-score > 2) GR00366-A-57 9.74 KISS1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.74 FGFR1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.74 KISS1R
21 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.74 FGFR1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-97 9.74 LHB

MGI Mouse Phenotypes related to Hypogonadism:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.17 CHD7 FGFR1 FSHB GNRH1 GNRHR KISS1
2 cellular MP:0005384 10.1 CHD7 DCAF17 DUSP6 FGFR1 FSHB GNRHR
3 growth/size/body region MP:0005378 10.03 CHD7 DUSP6 FGFR1 GNRH1 GNRHR KISS1
4 homeostasis/metabolism MP:0005376 10 CHD7 DUSP6 FGFR1 FSHB GNRH1 GNRHR
5 digestive/alimentary MP:0005381 9.97 CHD7 FGFR1 GNRH1 GNRHR KISS1 KISS1R
6 nervous system MP:0003631 9.7 CHD7 FGF17 FGFR1 GNRH1 KISS1 KISS1R
7 reproductive system MP:0005389 9.5 CHD7 DCAF17 FGFR1 FSHB GNRH1 GNRHR
Sources

Drugs & Therapeutics for Hypogonadism

About this section

Drugs for Hypogonadism (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 221)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Menotropins Approved Phase 4,Not Applicable 9002-68-0, 61489-71-2 5360545
2
Testosterone Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-22-0, 481-30-1 6013 10204
3
Testosterone enanthate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 315-37-7 9416
4
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-18-4 6010
5
Testosterone undecanoate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 5949-44-0
6
Anastrozole Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 120511-73-1 2187
7
Dihydrotachysterol Approved Phase 4,Phase 2,Phase 1 67-96-9 5281010 5311071
8
Polyestradiol phosphate Approved Phase 4,Phase 3,Not Applicable,Early Phase 1 28014-46-2
9
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable,Early Phase 1 50-28-2 5757
10
Dopamine Approved Phase 4,Not Applicable 62-31-7, 51-61-6 681
11
Liraglutide Approved Phase 4 204656-20-2 44147092
12
Zinc Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 7440-66-6 32051
13
Dutasteride Approved, Investigational Phase 4,Phase 2,Phase 1 164656-23-9 152945 6918296
14
Progesterone Approved, Vet_approved Phase 4,Phase 3,Not Applicable 57-83-0 5994
15
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
16
Metformin Approved Phase 4,Phase 3,Phase 2 657-24-9 14219 4091
17 Nutmeg Approved Phase 4
18
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable 7440-70-2 271
19
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 1406-16-2
20
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2 50-14-6 5280793
21
Vitamin D3 Approved, Nutraceutical Phase 4,Phase 3 67-97-0 5280795 6221
22
N,N-dimethylarginine Experimental Phase 4 30315-93-6 123831
23 Chorionic Gonadotropin Phase 4,Phase 3,Phase 2,Not Applicable
24 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
25 Fertility Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
26 Follicle Stimulating Hormone Phase 4,Phase 3,Phase 2,Not Applicable
27 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
28 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
29 Phosphodiesterase 5 Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
30 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
31 Anabolic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
32 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Testosterone 17 beta-cypionate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
34 Phosphodiesterase Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
35 Vardenafil Dihydrochloride Phase 4
36 Vasodilator Agents Phase 4,Not Applicable,Early Phase 1
37 Androgens Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
38 Aromatase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
39 Estrogen Receptor Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
40 Estrogen Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
41 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
42 Estrogens Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2
44 Calcium, Dietary Phase 4,Phase 3,Phase 2,Not Applicable
45 Estradiol 17 beta-cypionate Phase 4,Phase 3,Not Applicable,Early Phase 1
46 Estradiol 3-benzoate Phase 4,Phase 3,Not Applicable,Early Phase 1
47 Neurotransmitter Agents Phase 4,Not Applicable
48 Dopamine Agents Phase 4,Not Applicable
49 Central Nervous System Depressants Phase 4,Phase 2,Phase 1
50 Dopamine agonists Phase 4,Not Applicable

Interventional clinical trials:

(show top 50) (show all 363)
# Name Status NCT ID Phase Drugs
1 Human Menopausal Gonadotropin Combining With Human Chorionic Gonadotropin Treat Congenital Hypogonadotropic Hypogonadism Unknown status NCT02880280 Phase 4 Human Menopausal Gonadotropin;Human Chorionic Gonadotropin
2 Efficacy and Safety of Pulsatile Gonadotropin Releasing Hormone Pump Treatment in Patients With Idiopathic Hypogonadotropic Hypogonadism Unknown status NCT02310074 Phase 4 Pulsatile Gonadotropin Releasing Hormone;Human chorionic gonadotropin;Urinary Follicle-Stimulating Hormone
3 Comparison of Assisted Reproductive Technology (ART) Outcomes Between Two Protocols of Induction of Ovulation in Patients With Hypogonadotropic Hypogonadism Unknown status NCT02140515 Phase 4 Lutropin alfa;Follitropin alfa and Lutropin alfa
4 Effect of Testosterone on Endothelial Function and Microcirculation in Type 2 Diabetic Patients With Hypogonadism Unknown status NCT01084369 Phase 4 Testosterone
5 Aromatase Inhibitors and Weight Loss in Severely Obese Hypogonadal Male Veterans (Pilot) Unknown status NCT02959853 Phase 4 Anastrazole
6 Effect of Androgel on Type 2 Diabetic Males With Hypogonadism Unknown status NCT00350701 Phase 4 androgel;androgel 10g;placebo
7 Odense Androgen Study - The Effect of Testim and Training in Hypogonadal Men Unknown status NCT00700024 Phase 4 Testim;placebo
8 Testosterone for Peripheral Vascular Disease Unknown status NCT00504712 Phase 4 Testosterone;0.9% saline
9 Open-Label Study, Evaluating Patient Satisfaction and Symptom Improvement When Treating Male Hypogonadism With Natesto™ Completed NCT02937740 Phase 4 NATESTO Testosterone Nasal Gel
10 Effects of Medications in Patients With Hypogonadism Completed NCT01601327 Phase 4 Testosterone enanthate (Sustanon 250 mg);Human chorionic gonadotropin (hCG) (Pregnyl 5000 IU);Testosteron gel (Testojel 50 mg)
11 Testosterone Replacement Therapy and Liraglutide Effects on Weight Loss in Hypogonadism. Completed NCT03619330 Phase 4 liraglutide;Testosterone
12 Testosterone Replacement Therapy Decreases Plasma Paraoxonase 1 Enzyme Activity In Male Patients With Hypogonadism Completed NCT01107067 Phase 4 Sustanon
13 Endothelial Dysfunction, Inflammation and Insulin Resistance in Congenital Hypogonadism and Effect of Testosteron Replacement Therapy Completed NCT02171390 Phase 4 Testosterone 250mg injection;Testosteron 50 mg transdermal gel
14 Visceral Adiposity Index and Triglyceride/High-density Lipoprotein Cholesterol Ratio in the Congenital Hypogonadotropic Hypogonadism and Effect of Testosteron Treatment Completed NCT02111434 Phase 4 Testosterone
15 Metabolic Syndrome Criteria and the Effect of Testosterone Treatment in Young Men With Hypogonadism Completed NCT01160341 Phase 4 Testosteron
16 Sequential Therapy for Hypogonadotropic Hypogonadism Completed NCT01403532 Phase 4 Traditional intervention for HH using HCG and FSH;Sequential intervention for HH using HCG and FSH;Sequential intervention for HH using HCG and FSH plus zinc
17 The Effect of Testosteron Replacement Treatment on the Fibroblast Growth Factor-23, Asymmetric Dimethylarginine and Vitamin D Levels in the Congenital Hypogonadotropic Hypogonadism Completed NCT02111473 Phase 4 Testosterone
18 The Effect of Testosterone Replacement on Endothelial Dysfunction, Inflammation and Insulin Resistance in Male Hypogonadotrophic Hypogonadism Completed NCT01533129 Phase 4 Testogel 50 mg transdermal gel;Testosterone 250mg injection
19 Vitamin D Treatment and Hypogonadism in Men Completed NCT01748370 Phase 4 Vitamin D supplementation in hypogonadal men;Vitamin D supplementation in eugonadal men;Placebo hypogonadal;Placebo eugonadal
20 Effects of Testosterone on Myocardial Repolarization Completed NCT03126656 Phase 4 Testosterone Undecanoate
21 The Effect of Testosterone Replacement on the High Density Lipoprotein Cholesterol Subgroups Completed NCT01454011 Phase 4 Testosteron 250mg injection;Testosterone 50mg transdermal application
22 Testosterone Replacement in Men With Diabetes and Obesity Completed NCT01127659 Phase 4 testosterone;placebo
23 MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism Completed NCT02102646 Phase 4 Triptorelin
24 The Therapy of Nebido as Mono or in Combination With PDE-5 Inhibitors in Hypogonadal Patients With Erectile Dysfunction Completed NCT00421460 Phase 4 Testosterone Undecanoate,1000mg
25 TRADE-Testosterone Replacement and Dutasteride Effectiveness Completed NCT00194675 Phase 4 Dutasteride;Testosterone gel;Placebo dutasteride
26 TRT on BPH Hypoganadal MetS Patients. Florence-PROTEST Completed NCT02366975 Phase 4 Testosterone gel 2%
27 Efficacy of Fenugreek Seed and Lespedeza Cuneata in TDS Completed NCT03057899 Phase 4 TFG capsules (200 mg /capsule);Placebo oral capsule
28 The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel Completed NCT01893281 Phase 4 Topical Testosterone Solution
29 Efficacy Study for Use of Dutasteride (Avodart) With Testosterone Replacement Completed NCT00752869 Phase 4 dutasteride;placebo
30 Effect of Testosterone Replacement on Insulin Resistance Completed NCT00487734 Phase 4 Placebo for testosterone gel
31 Testosterone Replacement in Diabetes With Vascular Disease (Version 2) Completed NCT00355537 Phase 4 Testosterone;0.9% saline
32 Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism Completed NCT00837616 Phase 4 17 B estradiol orally;17 B estradiol
33 Testosterone for Men With Insulin Treated Type 2 Diabetes Completed NCT00349362 Phase 4 Testosterone;0.9% saline
34 Testosterone Replacement in Metabolic Syndrome and Inflammation Completed NCT01123278 Phase 4 Testosterone;Placebo
35 Testosterone Replacement in Older Men and Atherosclerosis Progression Completed NCT00287586 Phase 4 Testosterone Gel (Androgel);Placebo
36 Aripiprazole and Prolactin Study Completed NCT01085383 Phase 4 Aripiprazole
37 Subcutaneous vs. Intramuscular Testosterone Completed NCT03091348 Phase 4 Testosterone
38 Testosterone Therapy of Men With Type 2 Diabetes Mellitus (T2DM) Completed NCT01560546 Phase 4 Testosterone;Placebo
39 Study on Effects of Testosterone Replacement Therapy in Hypogonadal Type 2 Diabetic Patients" (SETH2) Completed NCT03792321 Phase 4 Testosterone Undecanoate;Placebo
40 Severe LH Suppressed Patients After Administration of a GnRH Antagonist Completed NCT01936077 Phase 4 Recombinant LH (Luveris)
41 FSH/LH Ratio as a Predictor of IVF Outcome in Young and Older Women Completed NCT02674178 Phase 4
42 Neuroendocrine Dysfunction in Traumatic Brain Injury: Effects of Testosterone Therapy Completed NCT01201863 Phase 4 Androgel (Testosterone Gel);Androgel Placebo
43 The Health Influences of Puberty (HIP) Study Completed NCT01775813 Phase 4 Metformin
44 Aromatase Inhibitors and Weight Loss in Severely Obese Men With Hypogonadism Recruiting NCT03490513 Phase 4 anastrozole (1 mg/day);Placebo
45 Testosterone Therapy in Hypogonadal Men Treated With Opioids Recruiting NCT02433730 Phase 4 Testosterone;placebo
46 Natesto Effects on Testosterone, Luteinizing Hormone, Follicle Stimulating Hormone and Semen Parameters Recruiting NCT03203681 Phase 4 NATESTO® (4.5% nasal testosterone) Nasal Gel
47 A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men ( TRAVERSE ) Recruiting NCT03518034 Phase 4 Testosterone;Placebo
48 Periodontal Profile of Hypogonadic Men Recruiting NCT03176537 Phase 4 Testosterone gel;Placebos
49 Xiaflex® Plus Testosterone Treatment Pilot Study Protocol Recruiting NCT03815331 Phase 4 Xiaflex®;Aveed
50 Pilot E2 for Hypogonadal Women With CFBD Recruiting NCT03724955 Phase 4 Estradiol 2 mg

Search NIH Clinical Center for Hypogonadism

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: hypogonadism

Sources

Genetic Tests for Hypogonadism

About this section

Genetic tests related to Hypogonadism:

# Genetic test Affiliating Genes
1 Hypogonadism 30
Sources

Anatomical Context for Hypogonadism

About this section

MalaCards organs/tissues related to Hypogonadism:

42
Bone, Pituitary, Prostate, Testes, Ovary, Brain, Endothelial
Sources

Publications for Hypogonadism

About this section

Articles related to Hypogonadism:

(show top 50) (show all 2644)
# Title Authors Year
1
Effect of Korean Herbal Formula (Modified Ojayeonjonghwan) on Androgen Receptor Expression in an Aging Rat Model of Late Onset Hypogonadism. ( 30584994 )
2019
2
Are hypothyroidism and hypogonadism clinically relevant in patients with malignant gliomas? A longitudinal trial in patients with glioma. ( 30712840 )
2019
3
Are hypothyroidism and hypogonadism clinically relevant in patients with malignant gliomas? A longitudinal trial in patients with glioma. ( 30389240 )
2019
4
Re: Trends in Testosterone Prescribing for Age-Related Hypogonadism in Men with and without Heart Disease. ( 30888894 )
2019
5
Hypogonadism in Men With Hepatitis C: What Is a Clinician to Do? ( 30715228 )
2019
6
Hypogonadism in Children with a Previous History of Cancer: Endocrine Management and Follow-Up. ( 30703774 )
2019
7
Effects of liraglutide on obesity-associated functional hypogonadism in men. ( 30707677 )
2019
8
Remission of type 2 diabetes and pleiotropic effects of long-term testosterone treatment for "late-onset" hypogonadism: A case report. ( 30719309 )
2019
9
High frequency of CHD7 mutations in congenital hypogonadotropic hypogonadism. ( 30733481 )
2019
10
The Optimal Indication for Testosterone Replacement Therapy in Late Onset Hypogonadism. ( 30736442 )
2019
11
Re: Clomiphene Citrate and Human Chorionic Gonadotropin Are Both Effective in Restoring Testosterone in Hypogonadism: . ( 30747887 )
2019
12
Re: Effects of Clomiphene Citrate on Male Obesity-Associated Hypogonadism: . ( 30759646 )
2019
13
Use of medicinal doses of zinc as a safe and efficient coadjutant in the treatment of male hypogonadism. ( 30767598 )
2019
14
Prevalence of Low Bone Density and Comorbid Hypogonadism in Patients With Chronic Pancreatitis. ( 30768576 )
2019
15
Long-term treatment with testosterone undecanoate injections in men with hypogonadism alleviates erectile dysfunction and reduces risk of major adverse cardiovascular events, prostate cancer, and mortality. ( 30782054 )
2019
16
Managing congenital hypogonadotrophic hypogonadism: a contemporary approach directed at optimizing fertility and long-term outcomes in males. ( 30800268 )
2019
17
High density lipoprotein function is reduced in patients affected by genetic or idiopathic hypogonadism. ( 30835274 )
2019
18
Xyosted--a testosterone auto-injector for hypogonadism. ( 30845097 )
2019
19
Congenital Hypogonadotrophic Hypogonadism: Minipuberty and the Case for Neonatal Diagnosis. ( 30846970 )
2019
20
Testosterone replacement in congenital hypogonadotropic hypogonadism maintains bone density but has only limited osteoanabolic effects. ( 30851011 )
2019
21
Late-onset Hypogonadism and Testosterone Therapy - A Summary of Guidelines from the American Urological Association and the European Association of Urology. ( 30858073 )
2019
22
Testosterone Therapy in Men With Hypogonadism Prevents Progression From Prediabetes to Type 2 Diabetes: Eight-Year Data From a Registry Study. ( 30862651 )
2019
23
The experience of a tertiary unit on the clinical phenotype and management of hypogonadism in female adolescents and young adults with transfusion dependent thalassemia. ( 30889170 )
2019
24
Ablating astrocyte insulin receptors leads to delayed puberty and hypogonadism in mice. ( 30893295 )
2019
25
Reversible male hypogonadotropic hypogonadism due to energy deficit. ( 30903626 )
2019
26
Three Siblings with Idiopathic Hypogonadotropic Hypogonadism in a Nonconsanguineous Family: A Novel KISS1R/GPR54 Loss-of-Function Mutation ( 30905142 )
2019
27
Gonadotropin replacement in male thalassemia major patients with arrested puberty and acquired hypogonadotropic hypogonadism (AAH): preliminary results and potential factors affecting induction of spermatogenesis. ( 30298384 )
2019
28
Re: Testosterone Therapy in Men with Hypogonadism: An Endocrine Society Clinical Practice Guideline. ( 30577344 )
2019
29
Effect of testosterone on FGF2, MRF4 and myostatin in hypogonadotropic hypogonadism: relevance to muscle growth. ( 30629183 )
2019
30
Physical activity counteracts metabolic syndrome-induced hypogonadotropic hypogonadism and erectile dysfunction in the rabbit. ( 30645174 )
2019
31
The severity of hypogonadism symptoms and its risk factors among male employees of Tehran University of Medical Sciences. ( 30651006 )
2019
32
Important lessons about testosterone therapy- weight loss vs. testosterone therapy for symptom resolution, classical vs. functional hypogonadism, and shortterm vs. lifelong testosterone therapy. ( 30651008 )
2019
33
Correlation between serum P450arom and sex hormones in males with late-onset hypogonadism: a pilot study. ( 30657548 )
2019
34
Clarifying the link between ibuprofen and hypogonadism. ( 30664744 )
2019
35
Evidence for a Common Genetic Origin of Classic and Milder Adult-Onset Forms of Isolated Hypogonadotropic Hypogonadism. ( 30669598 )
2019
36
Clinical management of congenital hypogonadotropic hypogonadism. ( 30698671 )
2019
37
Predictive factors for pituitary response to pulsatile GnRH therapy in patients with congenital hypogonadotropic hypogonadism. ( 29516878 )
2018
38
The effects of low-dose human chorionic gonadotropin combined with human menopausal gonadotropin protocol on women with hypogonadotropic hypogonadism undergoing ovarian stimulation for in vitro fertilization. ( 28960429 )
2018
39
Hypogonadism as a Reversible Cause of Torsades de Pointes in Men. ( 29967236 )
2018
40
Klinefelter syndrome: more than hypogonadism. ( 29382506 )
2018
41
Prevalence and treatment of central hypogonadism and hypoandrogenism in women with hypopituitarism. ( 29789996 )
2018
42
Symptomatic Androgen Deficiency Develops only When Both Total and Free Testosterone Decline in Obese Men Who may have Incident Biochemical Secondary Hypogonadism: Prospective Results from the EMAS. ( 29855071 )
2018
43
FGFR1 disruption identified by whole genome sequencing in a male with a complex chromosomal rearrangement and hypogonadotropic hypogonadism. ( 29160040 )
2018
44
Screening for Hypogonadism in Primary Healthcare: How to do this Effectively. ( 29365335 )
2018
45
Health-related physical fitness and quality of life in men with congenital hypogonadotropic hypogonadism. ( 29430665 )
2018
46
MRI of ectopic posterior pituitary gland with dysgenesis of pituitary stalk in a patient with hypogonadotropic hypogonadism. ( 29887929 )
2018
47
Rapid recovery of hypogonadism in male patients with end stage renal disease after renal transplantation. ( 29392618 )
2018
48
Downregulation of leptin receptor and kisspeptin/GPR54 in the murine hypothalamus contributes to male hypogonadism caused by high-fat diet-induced obesity. ( 29948931 )
2018
49
Sertraline Suppresses Testis and Adrenal Steroid Production and Steroidogenic Gene Expression While Increasing LH in Plasma of Male Rats Resulting in Compensatory Hypogonadism. ( 29850907 )
2018
50
Myotonic dystrophy type 1 with diabetes mellitus, mixed hypogonadism and adrenal insufficiency. ( 29367875 )
2018
Sources

Variations for Hypogonadism

About this section
Sources

Expression for Hypogonadism

About this section
Search GEO for disease gene expression data for Hypogonadism.
Sources

Pathways for Hypogonadism

About this section

Pathways related to Hypogonadism according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Signaling by GPCR 67
Show member pathways
 13.73 ANOS1 DUSP6 FGF17 FGFR1 FSHB GNRH1
2
Peptide ligand-binding receptors 67
Show member pathways
 12.98 FSHB GNRH1 GNRHR KISS1 KISS1R LHB
3
Immune response IFN alpha/beta signaling pathway 23
Show member pathways
 11.88 FGF17 FGFR1 GNRH1 LHB
4
G alpha (s) signalling events 67
11.77 FSHB LHB LHCGR
5
Immune response IFN gamma signaling pathway 23
Show member pathways
 11.72 FGF17 FGFR1 GNRH1 LHB
6
G-protein signaling_RhoA regulation pathway 23
11.31 FGF17 FGFR1 GNRH1 LHB
7
Ovarian steroidogenesis 38
11.12 FSHB LHB LHCGR
8
Hormone ligand-binding receptors 67
10.14 FSHB GNRH1 GNRHR LHB LHCGR
Sources

GO Terms for Hypogonadism

About this section

Cellular components related to Hypogonadism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.28 ANOS1 FGF17 FGFR1 FSHB GNRH1 KISS1

Biological processes related to Hypogonadism according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 male gonad development GO:0008584 9.67 LHB LHCGR NR0B1
2 female pregnancy GO:0007565 9.65 FSHB GNRH1 TAC3
3 fibroblast growth factor receptor signaling pathway GO:0008543 9.58 ANOS1 FGF17 FGFR1
4 peptide hormone processing GO:0016486 9.51 FSHB LHB
5 male sex determination GO:0030238 9.46 GNRH1 NR0B1
6 hormone-mediated signaling pathway GO:0009755 9.43 FSHB LHB LHCGR
7 cellular response to gonadotropin stimulus GO:0071371 9.37 LHCGR NSMF
8 G protein-coupled receptor signaling pathway GO:0007186 9.36 FSHB GNRH1 GNRHR KISS1 KISS1R LHB
9 tachykinin receptor signaling pathway GO:0007217 9.32 TAC3 TACR3
10 neuropeptide signaling pathway GO:0007218 9.26 KISS1R PROK2 PROKR2 TAC3
11 progesterone biosynthetic process GO:0006701 9.16 FSHB LHB
12 signal transduction GO:0007165 10.03 FGF17 GNRH1 GNRHR KISS1R LHB LHCGR

Molecular functions related to Hypogonadism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.13 FSHB GNRH1 LHB
2 protein-hormone receptor activity GO:0016500 8.62 GNRHR LHCGR
Sources

Sources for Hypogonadism

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....